Placeholder Banner

BIO Comments on FDA Draft Guidance on Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings

December 17, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings, which FDA says is intended to assist sponsors of drug and biological products for rare diseases in planning and conducting more efficient and productive pre-investigational new drug application (pre-IND) meetings.

BIO applauds the FDA’s initiative to advance drug development and review for therapies to treat rare diseases. It’s estimated there are 7,000 identified rare diseases, but only 5% have an approved therapy. This guidance provides important information to drug developers to make the drug development process more consistent, transparent, and efficient. BIO provided general comments and line edits.

Download Full Comments Below
BIO Letter Rare Diseases Early Drug Development And The Role Of PreIND Meetings FDA–2018-D-3268
Read full comment letter below
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…